Guideline-Consistent Treatment for Inflammatory Breast Cancer Provides Associated Survival Benefit Independent of Age.

Abstract

Guideline-consistent treatment (GCT) for inflammatory breast cancer (IBC) includes neoadjuvant chemotherapy (NAC), modified radical mastectomy (MRM), and radiation. We hypothesized that younger patients more frequently receive GCT, resulting in survival differences. Using the National Cancer Database (2004-2018), female patients with unilateral IBC (by histology code and clinical stage T4d) were stratified by age (< 50, 50-65, > 65years). Factors associated with NAC, MRM, radiation, and "GCT" (defined as all three treatments) were identified using multivariable logistic regression. Multivariable Cox proportional hazards regression identified predictors of overall survival. Of 3278 IBC patients, 30% were younger than 50years, 44% were 50-65years of age, and 26% were older than 65years. The youngest group comprised the greatest proportion of non-White patients ([35%] vs. [29%] age 50-65years and [23%]age > 65years, p < 0.001) and was most often treated at academic facilities ([33%] vs. [28%]age 50-65years; and [23%]age > 65, p < 0.001). Patients older than 65years received NAC, MRM, and radiation less frequently, and only 35% underwent GCT (vs.[57%] age 50-65years and[52%] age < 50years; p < 0.001). On multivariable logistic regression, age older than 65years independently predicted omission of NAC (odds ratio [OR], 0.36), MRM (OR, 0.56), and radiation (OR, 0.56) (all p < 0.001), and patients older than 65years also were less likely to undergo GCT than patients 50-65years of age (OR, 0.65; p = 0.001). GCT was associated with superior overall survival in all three age groups ([hazard ratio {HR}, 0.61]age < 50 years,[HR, 0.62] age 50-65years, [HR, 0.53]age > 65 years; all p < 0.001). Advanced age alone should not limit receipt of GCT for IBC. Multimodal care should be performed for IBC patients of all ages to improve oncologic outcomes for this aggressive breast cancer subtype.